RPG Life Sciences’ wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), has entered into a Business Transfer Agreement to acquire the API and intermediates business undertaking of Raghava Life Sciences Private Limited through a slump sale on a going-concern basis.

The transaction is subject to customary closing conditions and regulatory approvals.

The acquisition is part of RPGAP’s buy-and-build strategy to expand its manufacturing footprint, product portfolio, regulatory capabilities and customer access and create a scaled, integrated API-focused organisation.

The transaction follows RPGAP’s recent acquisition of Actis Generics and is expected to further strengthen its presence in the growing API market through increased scale, operational synergies, deeper integration and expanded commercial capabilities.

Raghava operates a modern API manufacturing facility near Hyderabad, spread across approximately 9 acres, with around 300 KL of installed capacity and a dedicated R&D setup.

The facility is WHO-GMP and EU-GMP approved and has received significant investment towards capacity expansion in recent years. Its regulatory approvals, manufacturing capacity and chemistry capabilities are expected to provide RPGAP with an expanded API manufacturing base.

Raghava’s portfolio includes 22 commercialised APIs and seven development-stage assets spanning diabetes, cardiovascular, CNS and other therapeutic areas. The portfolio is supported by international regulatory credentials including CEP, EU Written Confirmation and KDMF approvals.

RPGAP expects to unlock synergies across the Raghava acquisition, Actis and its existing network through backward integration, improved capacity utilisation, cost efficiencies and selected product transfers.

The combined business is also expected to benefit from stronger business development, broader market access, deeper customer coverage and more focused portfolio execution.

The acquisition will be funded in line with the recent equity raise announced by RPGAP.

Ashok Nair, Managing Director, RPG Life Sciences Limited, said: "This acquisition marks an important addition to the RPG Active Pharma Limited consolidated organization. It brings together a high-quality manufacturing asset, a broad portfolio of commercialized APIs, established regulatory credentials and strong customer relationships.”

"“The real opportunity lies in unlocking the potential of the asset through stronger commercialization, improved capacity utilization and integration across the organization. By combining these manufacturing and product capabilities with Actis' intermediate strengths and RPGAP's governance, talent and market access, we intend to build a larger presence and capture a greater share of the growing API market,” added Nair.

Lohith Ponguleti, Managing Director, Raghava Life Sciences Private Limited, said: "We are pleased to see Raghava Life Sciences Private Limited embark on its next phase of growth as part of RPG. Over the years, we have built a differentiated business anchored by an EU-GMP approved manufacturing facility, strong technical capabilities and a portfolio with significant growth potential.”